Cargando…
IRS1‐ rs10498210 G/A and CCR5‐59029 A/G polymorphisms in patients with type 2 diabetes in Kurdistan
BACKGROUND: The insulin receptor substrate 1 (IRS1) is a critical factor in the signaling pathway for insulin, and mutations in this gene have been reported, which contribute to the ability to develop type 2 diabetes. The polymorphisms in the promoter region of C‐C motif chemokine receptor5 (CCR5) a...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503169/ https://www.ncbi.nlm.nih.gov/pubmed/30884193 http://dx.doi.org/10.1002/mgg3.631 |
_version_ | 1783416370342395904 |
---|---|
author | Keshavarzi, Fatemeh Golsheh, Shadi |
author_facet | Keshavarzi, Fatemeh Golsheh, Shadi |
author_sort | Keshavarzi, Fatemeh |
collection | PubMed |
description | BACKGROUND: The insulin receptor substrate 1 (IRS1) is a critical factor in the signaling pathway for insulin, and mutations in this gene have been reported, which contribute to the ability to develop type 2 diabetes. The polymorphisms in the promoter region of C‐C motif chemokine receptor5 (CCR5) are also being studied as candidates for susceptibility to develop type 2 diabetes. The aim of the current study was to determine the relationship between IRS1 and CCR5 polymorphisms with type 2 diabetes in the Kurdistan population. METHODS: Genomic DNA was isolated from the blood by salt extraction method and the polymorphisms were examined using Restriction Fragment Length Polymorphism (RFLP) method. RESULTS: The results of current study indicated that the frequency of AA genotype in type 2 diabetic patients in both CCR5 (OR = 2.9, p = 0.04) and IRS1 (OR = 3.3, p = 0.036) were significantly more than controls. CONCLUSION: According to the results of this study, the presence of AA genotype in both CCR5 and IRS1 is associated with type 2 diabetes. There was no significant association between AG or GG genotypes with type 2 diabetes. |
format | Online Article Text |
id | pubmed-6503169 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-65031692019-05-10 IRS1‐ rs10498210 G/A and CCR5‐59029 A/G polymorphisms in patients with type 2 diabetes in Kurdistan Keshavarzi, Fatemeh Golsheh, Shadi Mol Genet Genomic Med Original Articles BACKGROUND: The insulin receptor substrate 1 (IRS1) is a critical factor in the signaling pathway for insulin, and mutations in this gene have been reported, which contribute to the ability to develop type 2 diabetes. The polymorphisms in the promoter region of C‐C motif chemokine receptor5 (CCR5) are also being studied as candidates for susceptibility to develop type 2 diabetes. The aim of the current study was to determine the relationship between IRS1 and CCR5 polymorphisms with type 2 diabetes in the Kurdistan population. METHODS: Genomic DNA was isolated from the blood by salt extraction method and the polymorphisms were examined using Restriction Fragment Length Polymorphism (RFLP) method. RESULTS: The results of current study indicated that the frequency of AA genotype in type 2 diabetic patients in both CCR5 (OR = 2.9, p = 0.04) and IRS1 (OR = 3.3, p = 0.036) were significantly more than controls. CONCLUSION: According to the results of this study, the presence of AA genotype in both CCR5 and IRS1 is associated with type 2 diabetes. There was no significant association between AG or GG genotypes with type 2 diabetes. John Wiley and Sons Inc. 2019-03-18 /pmc/articles/PMC6503169/ /pubmed/30884193 http://dx.doi.org/10.1002/mgg3.631 Text en © 2019 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Articles Keshavarzi, Fatemeh Golsheh, Shadi IRS1‐ rs10498210 G/A and CCR5‐59029 A/G polymorphisms in patients with type 2 diabetes in Kurdistan |
title |
IRS1‐ rs10498210 G/A and CCR5‐59029 A/G polymorphisms in patients with type 2 diabetes in Kurdistan |
title_full |
IRS1‐ rs10498210 G/A and CCR5‐59029 A/G polymorphisms in patients with type 2 diabetes in Kurdistan |
title_fullStr |
IRS1‐ rs10498210 G/A and CCR5‐59029 A/G polymorphisms in patients with type 2 diabetes in Kurdistan |
title_full_unstemmed |
IRS1‐ rs10498210 G/A and CCR5‐59029 A/G polymorphisms in patients with type 2 diabetes in Kurdistan |
title_short |
IRS1‐ rs10498210 G/A and CCR5‐59029 A/G polymorphisms in patients with type 2 diabetes in Kurdistan |
title_sort | irs1‐ rs10498210 g/a and ccr5‐59029 a/g polymorphisms in patients with type 2 diabetes in kurdistan |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503169/ https://www.ncbi.nlm.nih.gov/pubmed/30884193 http://dx.doi.org/10.1002/mgg3.631 |
work_keys_str_mv | AT keshavarzifatemeh irs1rs10498210gaandccr559029agpolymorphismsinpatientswithtype2diabetesinkurdistan AT golshehshadi irs1rs10498210gaandccr559029agpolymorphismsinpatientswithtype2diabetesinkurdistan |